Analysts Set Expectations for CLRB Q1 Earnings

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Research analysts at Roth Capital issued their Q1 2025 EPS estimates for Cellectar Biosciences in a research note issued to investors on Monday, November 18th. Roth Capital analyst J. Aschoff expects that the biopharmaceutical company will post earnings of ($0.26) per share for the quarter. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.57) per share.

A number of other equities research analysts have also commented on CLRB. Oppenheimer decreased their price objective on shares of Cellectar Biosciences from $14.00 to $12.00 and set an “outperform” rating on the stock in a report on Tuesday. StockNews.com raised shares of Cellectar Biosciences to a “sell” rating in a research note on Thursday, September 26th.

Cellectar Biosciences Stock Performance

CLRB opened at $1.58 on Wednesday. The firm’s 50-day simple moving average is $2.05 and its 200-day simple moving average is $2.40. Cellectar Biosciences has a twelve month low of $1.39 and a twelve month high of $4.45. The firm has a market cap of $65.21 million, a price-to-earnings ratio of -0.91 and a beta of 1.00.

Cellectar Biosciences (NASDAQ:CLRB) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter.

Institutional Trading of Cellectar Biosciences

Several hedge funds have recently bought and sold shares of CLRB. Geode Capital Management LLC grew its stake in shares of Cellectar Biosciences by 3.3% in the third quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock valued at $754,000 after buying an additional 11,266 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Cellectar Biosciences in the third quarter valued at $27,000. Rosalind Advisors Inc. grew its stake in shares of Cellectar Biosciences by 35.7% in the third quarter. Rosalind Advisors Inc. now owns 3,671,550 shares of the biopharmaceutical company’s stock valued at $7,857,000 after buying an additional 965,934 shares in the last quarter. Sequoia Financial Advisors LLC bought a new position in shares of Cellectar Biosciences in the third quarter valued at $51,000. Finally, XTX Topco Ltd grew its stake in shares of Cellectar Biosciences by 432.4% in the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 51,413 shares in the last quarter. 16.41% of the stock is currently owned by institutional investors and hedge funds.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.